ATE384725T1 - Pyrimido 4,5-d pyrimidinderivate mitantikrebswirkung - Google Patents

Pyrimido 4,5-d pyrimidinderivate mitantikrebswirkung

Info

Publication number
ATE384725T1
ATE384725T1 AT03810410T AT03810410T ATE384725T1 AT E384725 T1 ATE384725 T1 AT E384725T1 AT 03810410 T AT03810410 T AT 03810410T AT 03810410 T AT03810410 T AT 03810410T AT E384725 T1 ATE384725 T1 AT E384725T1
Authority
AT
Austria
Prior art keywords
pyrimido
pyrimidine derivatives
cancer effect
cancer
effect
Prior art date
Application number
AT03810410T
Other languages
English (en)
Inventor
Lee Apostle Mcdermott
Marek Kabat
Kin-Chun Luk
Pamela Rossman
Sung-Sau So
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE384725T1 publication Critical patent/ATE384725T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03810410T 2002-11-04 2003-10-27 Pyrimido 4,5-d pyrimidinderivate mitantikrebswirkung ATE384725T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42367002P 2002-11-04 2002-11-04

Publications (1)

Publication Number Publication Date
ATE384725T1 true ATE384725T1 (de) 2008-02-15

Family

ID=32312700

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03758072T ATE386744T1 (de) 2002-11-04 2003-10-27 Pyrimidoderivate mit antiproliferativer aktivität (ii)
AT03810410T ATE384725T1 (de) 2002-11-04 2003-10-27 Pyrimido 4,5-d pyrimidinderivate mitantikrebswirkung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03758072T ATE386744T1 (de) 2002-11-04 2003-10-27 Pyrimidoderivate mit antiproliferativer aktivität (ii)

Country Status (16)

Country Link
US (2) US7112676B2 (de)
EP (2) EP1560832B1 (de)
JP (2) JP2006507292A (de)
KR (4) KR100774230B1 (de)
CN (2) CN1711266A (de)
AR (2) AR041739A1 (de)
AT (2) ATE386744T1 (de)
AU (1) AU2003276190A1 (de)
BR (2) BR0315912A (de)
CA (2) CA2502182A1 (de)
DE (2) DE60318888T2 (de)
ES (2) ES2298622T3 (de)
MX (2) MXPA05004757A (de)
PL (2) PL376916A1 (de)
RU (2) RU2326882C2 (de)
WO (2) WO2004041821A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003903501A0 (en) * 2003-07-07 2003-07-24 Commonwealth Scientific And Industrial Research Organisation A method of forming a reflective authentication device
WO2005011597A2 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
FR2873127B1 (fr) 2004-07-13 2008-08-29 Omya Development Ag Procede de fabrication de particules pigmentaires autoliantes, seches ou en suspension ou dispersion aqueuses, contenant des matieres inorganiques et des liants
US7655651B2 (en) 2004-08-31 2010-02-02 Hoffmann-La Roche Inc. Amide derivatives of 3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
MX2007002089A (es) * 2004-08-31 2007-03-29 Hoffmann La Roche Derivados de amida de 7-amino-3-fenil-dihidropirimido[4,5-d]pirimidonas, su fabricacion y su uso como inhibidores de proteina cinasa.
PT1951684T (pt) * 2005-11-01 2016-10-13 Targegen Inc Inibidores de cinases de tipo biaril-meta-pirimidina
CA2636981A1 (en) 2006-01-31 2007-08-09 F. Hoffmann-La Roche Ag 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
CA2646369A1 (en) * 2006-03-29 2007-11-08 North Carolina State University Synthesis and regioselective substitution of 6-halo- and 6-alkoxy nicotine derivatives
WO2007136465A2 (en) * 2006-05-15 2007-11-29 Irm Llc Compositions and methods for fgf receptor kinases inhibitors
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
WO2010014939A1 (en) * 2008-07-31 2010-02-04 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
BRPI0919248A2 (pt) 2008-09-25 2019-09-24 Hoffmann La Roche derivados de 3-amino-indazol ou 3-amino-4,5,6,7-tetraidroindazol
EP2376494A4 (de) 2008-12-12 2012-07-11 Msd Kk Dihydropyrimidopyrimidinderivate
CA2745970A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
HUP0800768A2 (en) 2008-12-18 2012-08-28 Bioblocks Magyarorszag Gyogyszerkemiai Es Fejlesztoe Kft 1,3-heterocycles condensed with monoterpene skeleton, their use and pharmaceutical compositions comprising such compounds
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20100318651A1 (en) * 2009-06-10 2010-12-16 Everis, Inc. Network Communication System With Monitoring
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
DK3176170T3 (en) 2012-06-13 2019-01-28 Incyte Holdings Corp SUBSTITUTED TRICYCLIC RELATIONS AS FGFR INHIBITORS
SG10201610869TA (en) 2012-06-26 2017-02-27 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
JP6576325B2 (ja) 2013-03-15 2019-09-18 セルジーン シーエーアール エルエルシー ヘテロアリール化合物およびそれらの使用
SI2986610T1 (en) 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as inhibitors of FGFR
US9783504B2 (en) * 2013-07-09 2017-10-10 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
CA2954187C (en) 2014-07-21 2022-08-16 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
CA2954186A1 (en) 2014-07-21 2016-01-28 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
CA2955082A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3617205B1 (de) 2015-02-20 2021-08-04 Incyte Corporation Bicyclische heterocyclen als fgfr-inhibitoren
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CA3069016A1 (en) * 2016-07-05 2018-01-11 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
WO2018053373A1 (en) 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
US11285158B2 (en) 2017-02-28 2022-03-29 The General Hospital Corporation Uses of pyrimidopyrimidinones as SIK inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
AU2019262579A1 (en) 2018-05-04 2020-12-24 Incyte Corporation Salts of an FGFR inhibitor
CA3124678A1 (en) * 2018-12-27 2020-07-02 Zenon D. Konteatis Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Fgfr阻害剤としての三環式複素環
JP2023505257A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Fgfr阻害剤の誘導体
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4352059A1 (de) 2021-06-09 2024-04-17 Incyte Corporation Tricyclische heterocyclen als fgfr-inhibitoren

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949466A (en) 1958-03-04 1960-08-16 Parke Davis & Co Pyrimidine compounds and means of producing the same
NL6704601A (de) 1966-04-06 1967-10-09
US4425346A (en) 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
JPS60226882A (ja) 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
AU7622698A (en) 1996-12-05 1998-06-29 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
KR200143829Y1 (ko) * 1996-12-30 1999-06-15 양재신 연료펌프 교환시 연료의 비산 방지구
BR9911590A (pt) 1998-05-26 2001-02-13 Warner Lambert Co Pirimidinas bicìclicas e 3,4-diidropirimidinas bicìclicas como inibidores da proliferação celular
AU769989B2 (en) 1998-10-23 2004-02-12 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles
ATE353329T1 (de) 1999-10-21 2007-02-15 Hoffmann La Roche Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen
AU776695B2 (en) 1999-10-21 2004-09-16 F. Hoffmann-La Roche Ag Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
AR030053A1 (es) 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
EP1315726A1 (de) 2000-08-31 2003-06-04 F. Hoffmann-La Roche Ag 7-oxopyridopyrimidine als inhibitoren von zellvermehrung
KR20060111716A (ko) 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents

Also Published As

Publication number Publication date
WO2004041821A1 (de) 2004-05-21
KR100774230B1 (ko) 2007-11-07
CA2502182A1 (en) 2004-05-21
DE60319260D1 (de) 2008-04-03
AU2003274086B2 (en) 2008-07-10
EP1560832B1 (de) 2008-01-23
US7129351B2 (en) 2006-10-31
KR100763300B1 (ko) 2007-10-04
ES2300609T3 (es) 2008-06-16
MXPA05004756A (es) 2005-08-02
KR20070087657A (ko) 2007-08-28
RU2005117341A (ru) 2006-03-10
AU2003276190A1 (en) 2004-06-07
AR041739A1 (es) 2005-05-26
KR20070087689A (ko) 2007-08-28
DE60318888D1 (de) 2008-03-13
AU2003274086A1 (en) 2004-06-07
CN100420688C (zh) 2008-09-24
EP1560832A1 (de) 2005-08-10
ES2298622T3 (es) 2008-05-16
US20040110773A1 (en) 2004-06-10
CA2502180A1 (en) 2004-05-21
RU2326882C2 (ru) 2008-06-20
CN1711264A (zh) 2005-12-21
AR041738A1 (es) 2005-05-26
EP1560829A1 (de) 2005-08-10
JP2006513999A (ja) 2006-04-27
BR0315912A (pt) 2005-09-13
PL376924A1 (pl) 2006-01-09
BR0316001A (pt) 2005-09-13
RU2005117340A (ru) 2006-02-27
EP1560829B1 (de) 2008-02-20
KR100774231B1 (ko) 2007-11-07
RU2331641C2 (ru) 2008-08-20
KR100763299B1 (ko) 2007-10-04
PL376916A1 (pl) 2006-01-09
ATE386744T1 (de) 2008-03-15
US20050075272A1 (en) 2005-04-07
WO2004041822A1 (en) 2004-05-21
DE60319260T2 (de) 2009-03-05
JP2006507292A (ja) 2006-03-02
MXPA05004757A (es) 2005-08-02
CN1711266A (zh) 2005-12-21
KR20050074534A (ko) 2005-07-18
US7112676B2 (en) 2006-09-26
DE60318888T2 (de) 2009-01-08
KR20050074540A (ko) 2005-07-18

Similar Documents

Publication Publication Date Title
ATE384725T1 (de) Pyrimido 4,5-d pyrimidinderivate mitantikrebswirkung
NO20053955D0 (no) Pyrazolo [1,5-A] pyrimidinderivater
NO20054330D0 (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
NO20054331D0 (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
IS8406A (is) 5,7-díamínópýrasóló [4,3-d] pýrimidín með PDE-5 hindrandi virkni
DK1797099T3 (da) Piperidinylamino-thieno[2,3-D]pyrimidinforbindelser
DK1487805T3 (da) Pyrimidinderivater
ATE360632T1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate
HK1118556A1 (en) 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
DK1419152T3 (da) HIV-hæmmende pyrimidin-derivater
IS7872A (is) Pýrrólópýrimidín afleiður
DK1761542T3 (da) Octahydropyrrolo[3,4-C] pyrrolderivater og anvendelsen deraf som antivirusmidler
ATE388713T1 (de) 4-amino-6-phenyl-pyrrolo(2,3-d)pyrimidin derivate
DE60311101D1 (de) 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido und 2,3-dihydro-2h-pyrrolo (2,1-b)-chinazolinon-derivate
MA28813B1 (fr) Derives de pyrimidine
NO20053748D0 (no) Pyrrolopyridazinderivater.
NO20030878L (no) Shunt med flere innlöp
DK1622880T3 (da) Substituerede dihydroquinazoliner med antivirale egenskaber
DE602004029045D1 (de) Pyrrolo [3,4-c] pyrazole derivate mit kinase hemmender wirkung
DE60206946D1 (de) Substituierte 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)onderivate gegen neurodegenerative erkrankungen
DE60103909D1 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
ATE512148T1 (de) Pyrazolo- und imidazopyrimidinderivate
ATE326467T1 (de) Imidazo 1,2-aöpyridine
DE60211038D1 (de) Rollenstössel mit kaltvorverstellung
DE50106542D1 (de) Substituierte 3,4-dihydro-pyrido[1,2-a]pyrimidine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1560832

Country of ref document: EP

REN Ceased due to non-payment of the annual fee